From: Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H
Target Organ | TD | %CV | TD NE | Dynamic single | %CV | Dynamic single NE |
---|---|---|---|---|---|---|
Adrenals | 1.43E-02 | 1.7 | 1.65E-02 | 1.36E-02 | 1.0 | 1.44E-02 |
Brain | 3.08E-02 | 16.7 | 2.05E-02 | 8.61E-03 | 1.1 | 8.27E-03 |
Breasts | 7.71E-03 | 2.9 | 7.18E-03 | 8.88E-03 | 0.7 | 8.36E-03 |
Gallbladder wall | 1.86E-02 | 4.3 | 2.26E-02 | 1.56E-02 | 1.7 | 1.75E-02 |
LLI wall | 1.36E-02 | 4.0 | 1.28E-02 | 1.55E-02 | 0.8 | 1.52E-02 |
Small intestine | 1.24E-02 | 3.2 | 1.22E-02 | 1.37E-02 | 0.5 | 1.37E-02 |
Stomach wall | 1.11E-02 | 2.3 | 1.11E-02 | 1.20E-02 | 0.4 | 1.20E-02 |
ULI wall | 1.25E-02 | 2.4 | 1.27E-02 | 1.34E-02 | 0.6 | 1.36E-02 |
Heart wall | 1.76E-02 | 6.5 | 1.77E-02 | 2.09E-02 | 9.2 | 1.26E-02 |
Kidneys | 2.96E-02 | 8.4 | 7.07E-02 | 1.87E-02 | 9.1 | 4.06E-02 |
Liver | 5.84E-02 | 12.6 | 8.40E-02 | 3.14E-02 | 6.3 | 4.32E-02 |
Lungs | 1.64E-02 | 6.7 | 1.11E-02 | 2.17E-02 | 12.0 | 1.23E-02 |
Muscle | 9.82E-03 | 3.1 | 9.42E-03 | 1.10E-02 | 0.4 | 1.08E-02 |
Ovaries | 1.38E-02 | 4.0 | 1.30E-02 | 1.57E-02 | 0.7 | 1.54E-02 |
Pancreas | 1.40E-02 | 0.7 | 1.55E-02 | 1.37E-02 | 0.7 | 1.43E-02 |
Red marrow | 9.71E-03 | 2.0 | 9.41E-03 | 1.04E-02 | 0.4 | 1.03E-02 |
Osteogenic cells | 1.39E-02 | 3.6 | 1.26E-02 | 1.57E-02 | 0.8 | 1.53E-02 |
Skin | 7.22E-03 | 3.7 | 6.73E-03 | 8.17E-03 | 0.7 | 8.00E-03 |
Spleen | 1.52E-02 | 7.9 | 1.50E-02 | 1.15E-02 | 0.5 | 1.16E-02 |
Testes | 1.58E-02 | 6.6 | 1.13E-01 | 1.25E-02 | 5.1 | 6.41E-02 |
Thymus | 9.26E-03 | 3.5 | 8.39E-03 | 1.09E-02 | 0.8 | 1.01E-02 |
Thyroid | 8.86E-03 | 4.1 | 7.62E-03 | 1.01E-02 | 0.9 | 9.63E-03 |
Urinary bladder wall | 1.54E-01 | 0.3 | 1.54E-01 | 1.56E-01 | 0.0 | 1.56E-01 |
Uterus | 1.90E-02 | 2.9 | 1.82E-02 | 2.09E-02 | 0.5 | 2.06E-02 |
Total body | 1.19E-02 | 0.0 | 1.21E-02 | 1.18E-02 | 0.4 | 1.19E-02 |
Effective dose (mSv/MBq) | 1.88E-02 | 2.7 | 2.72E-02 | 1.84E-02 | 1.9 | 2.19E-02 |